Knee Osteoarthritis

Musculoskeletal·MeSH: Osteoarthritis, Knee

Prevalence

10000.0 / 100K

Incidence

600.0 / 100K/yr

11 drugs in development·9 companies·25 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
genvisc	Avanos Medical Inc. (AVNS)

Phase 3(4)

Drug	Company
Apitox (Apitoxin in South Korea)	Apimeds Pharmaceuticals US, Inc. (APUS)
lorecivivint	TG THERAPEUTICS, INC. (TGTX)
plx-pad	Pluri Inc. (PLUR)
ptp-01	Horizon Therapeutics Public Ltd Co (HZNP)

Phase 2(5)

Drug	Company
allocetra	Enlivex Ltd. (ENLV)
allojoin	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
dfv890	Novartis AG (NVS)
rejoin	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
resiniferatoxin	Sorrento Therapeutics, Inc. (SRNE)

Phase 1(1)

Drug	Company
dfv890	Novartis AG (NVS)

BioSniper tracks 11 drugs in development for Knee Osteoarthritis across 9 companies.

There are 25 clinical trials targeting Knee Osteoarthritis tracked by BioSniper.

The estimated prevalence of Knee Osteoarthritis is approximately 10000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.